Exelixis, Inc. (EXEL)
After hours:
Chart Events
Performance Outlook
| Previous Close | 17.42 |
| Open | 17.49 |
| Bid | 17.30 x 3000 |
| Ask | 17.78 x 1000 |
| Day's Range | 17.01 - 17.78 |
| 52 Week Range | 15.50 - 25.77 |
| Volume | |
| Avg. Volume | 2,091,281 |
| Market Cap | 5.622B |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | 34.84 |
| EPS (TTM) | 0.51 |
| Earnings Date | Feb 08, 2022 - Feb 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.77 |
- GuruFocus.com
Resonant Capital Advisors, LLC Buys Marqeta Inc, Vanguard Tax-Exempt Bond ETF, iShares National ...
Investment company Resonant Capital Advisors, LLC (Current Portfolio) buys Marqeta Inc, Vanguard Tax-Exempt Bond ETF, iShares National Muni Bond ETF, Apple Inc, Amazon.com Inc, sells Xilinx Inc, Biogen Inc, Citrix Systems Inc, Exelixis Inc, Citigroup Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Resonant Capital Advisors, LLC.
- Motley Fool
5 Value Stocks That Can Make You Richer in 2022
For more than a decade, growth stocks have been the talk of Wall Street. Since value stocks are profitable and time-tested, they're the perfect place for patient investors to put their money to work. Below are five value stocks that could make you richer in 2022.
- Business Wire
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
ALAMEDA, Calif., January 18, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced results for cabozantinib (CABOMETYX®) in combination with immunotherapies in patients with advanced colorectal cancer, including encouraging data from cohort 16 of the phase 1b COSMIC-021 trial of cabozantinib in combination with atezolizumab in patients with metastatic colorectal cancer who were previously treated with fluoropyrimidine-containing chemotherapy. Results from cohort 2 of the phase 2 CAMILLA trial of c
